- Glucuretics (SGLT2 inhibitors, gliflosine) in the treatment of diabetes2011 | Third Faculty of Medicine
- SGLT2 inhibitors in T2D and associated comorbidities differentiating within the class2019 | First Faculty of Medicine
- The position of SGLT2 inhibitors in current medicine2020 | First Faculty of Medicine
- SGLT2 inhibitors and atherosclerosis in a background of effect of gliflozins and heart failure2021 | First Faculty of Medicine
- Current use of SGLT2 inhibitors in type 2 diabetes mellitus2016 | First Faculty of Medicine
- The renoprotective effects of canagliflozin demonstrated in the CREDENCE study cannot yet be considered as an effect of the whole class of SGLT2 inhibitors2020 | Second Faculty of Medicine
- Current position of SGLT2 inhibitors (gliflozins) in the treatment of diabetes mellitus2018 | Second Faculty of Medicine
- Empagliflozin and current position SGLT2 inhibitors in the treatment of type 2 diabetes2015 | First Faculty of Medicine
- The position of SGLT2 inhibitors in current medical practice - update 20222022 | First Faculty of Medicine
- Renoprotective effects of SGLT2 inhibitors - gliflozins2021 | First Faculty of Medicine
- Empagliflozin - new SGLT2 inhibitor for diabetes mellitus treatment2014 | Third Faculty of Medicine, First Faculty of Medicine
- New mechanism of treatment DM: glifloziny, SGLT2 inhibitors2014 | Second Faculty of Medicine
- SGLT2 inhibitors in the treatment of type 1 diabetic patients2019 | First Faculty of Medicine
- New treatment options for chronic kidney disease - focused on SGLT2 inhibitors2021 | First Faculty of Medicine
- What connects SGLT2 inhibitors, diabetes mellitus, heart failure and empagliflozin?2022 | First Faculty of Medicine
- 2021 ACC update of the heart failure guidelines2021 | First Faculty of Medicine
- Expert opinion on the cooperation of diabetologists and internists with nephrologists in the care of patients with chronic kidney diseases +12022 | Third Faculty of Medicine, First Faculty of Medicine
- Expert opinion on the cooperation of diabetologists and internists with nephrologists in the care of patients with chronic kidney diseases +12022 | Third Faculty of Medicine, First Faculty of Medicine, Central Library of Charles University
- Dapagliflozin - a new option in treating type 2 diabetes mellitus2015 | Second Faculty of Medicine
- New perspectives in the treatment of chronic heart failure2023 | Faculty of Medicine in Pilsen
- News in the treatment of heart failure - gliflozins in patients with a mildly reduced and preserved ejection fraction2023 | First Faculty of Medicine
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes2020 | First Faculty of Medicine
- Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes2022 | First Faculty of Medicine
- The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus2021 | Publication without faculty affiliation
- Heart failure in patients with diabetes - treatment and prevention2019 | First Faculty of Medicine
- Empagliflozin: Basic clinical characteristics2015 | First Faculty of Medicine
- Current options for slowing the progression of chronic kidney disease2022 | First Faculty of Medicine
- Additional options in diabetes treatment - gliflozins2014 | Faculty of Medicine in Hradec Králové